Rethinking GLP-1 messaging and reviewing the FDA's peptide panel

Episode Description

Executive editor Jack O’Brien first met Wendy Lund, an honoree from our Pinnacle Awards and Women of Distinction program, in September of 2022.

Lund had just left her position as CEO of Agency 100 honoree GCI Health to serve as chief client officer for health and wellness at WPP.

Now in her new post as CEO of Stagwell-owned agency Allison, Lund joins this week’s podcast for an in-person interview with reporter Bella Czajkowski.

Lund dives into a recent HarrisX–Allison Worldwide study on how GLP-1s are reshaping attitudes toward weight loss and care.

The report was released late last month and chief among its numerous findings was the observation that GLP-1s have moved firmly into the mainstream, though the public conversation around them remains split between medical breakthrough and moral judgment.

As Wendy told Bella, “culture is shaping health, but health is also shaping culture.”

And for our Trends segment, O’Brien and Czajkowski are joined by editor-at-large Steve Madden for a conversation on all that went down during the FDA’s recent two-day advisory panel focused on peptides.